Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Capecitabine for HER2-Negative Breast Cancer with Brain Metastases
NCT04965064Phase 2Recruiting
- Sponsor
- University of Rochester
- Start
- Sep 2022
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by University of Rochester. Started Sep 2022; status: recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04965064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965064.